Neurocenter of Southern Switzerland, Lugano   Report issue

Academic/Hospital Phase 1 Phase 3 Phase 4
Founded: Lugano Switzerland (2009)

Organization Overview

First Clinical Trial
2009
NCT01067222
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Neurocenter (EOC) of Southern Switzerland, Lugano, Switzerland | Neurocenter of Southern Switzerland | Neurocenter of Southern Switzerland,Lugano

Active Ingredients

Drugs in Phase 4 Trials (2)

pramipexole (mirapex) (1 trial)

prednisone (meticorten) (1 trial)

Drugs in Phase 3 Trials (2)

modafinil (provigil) (2 trials)

pitolisant (Wakix) (2 trials)

Drugs in Phase 1 Trials (1)

autologous mesenchymal stem cell-derived neural progenitors (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cataplexy (Phase 3)

Multiple Sclerosis (Phase 4)

Multiple Sclerosis, Chronic Progressive (Phase 1)

Narcolepsy (Phase 3)

Neoplasm Metastasis (Phase 1)

Parasomnias (Phase 3)

Psychomotor Agitation (Phase 4)

Restless Legs Syndrome (Phase 4)

Sclerosis (Phase 4)

Sleepiness (Phase 3)

Sleep Wake Disorders (Phase 3)

Syndrome (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 5